Anbio Biotechnology
NNNNHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 5, 2026
Scan Results
Daily timeframePart of the healthcare sector, Anbio Biotechnology (NNNN) is listed under Medical Instruments & Supplies. At a $287.0M market cap, Anbio Biotechnology ranks as a micro-cap company within healthcare. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Market Cap
$287.0M
Beta
—
P/E (TTM)
46.71
P/E (Fwd)
—
EPS (TTM)
$0.14
EPS (Fwd)
—
ROE
27.1%
ROA
14.7%
Cash
$11.9M
Total Debt
$0
Free CF
-$9.6M
52W Change
-85.6%
Annual Financials
Cash vs Debt
Where NNNN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NNNN finished 65.82% below its 150-day moving average ($20.04) and 69.77% below its 200-day moving average ($22.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NNNN overbought or oversold?
At the September 3, 2026 close, NNNN's RSI(14) was 20.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Anbio Biotechnology reports $11.9M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$9.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 27.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 14.7% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $23.5M to $8.6M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Anbio Biotechnology and its sector.